FIGURE

Fig. 4

ID

ZDB-FIG-240202-4

Publication

Larsson et al., 2024 - Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer

Other Figures

All Figure Page

Back to All Figure Page

Fig. 4

Potency of the 2-drug combinations evaluated by SynergyFinder using inhibition (%) scores.

A Bortezomib + nedaplatin was a very potent drug combination and inhibited CAL-148 with a mean (47.9) and median (60.0) inhibition score. B Carboplatin + paclitaxel had the lowest inhibition scores, mean (13.4) and median (14.3). C Carboplatin + paclitaxel had the highest mean and median inhibition on the MDA-MB-468 cell line. D Bortezomib + nedaplatin had the highest inhibition on the HCC38 cell line and lowest inhibition on HCC1806. E Bortezomib + nedaplatin achieved 34.3% above maximal inhibition by bortezomib alone and F carboplatin + paclitaxel achieved 7.7% above the maximal inhibition by paclitaxel alone. Paired t-test was used to calculate statistically significant differences between inhibition following monotherapy or with 2-drug combinations. *P < 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Cell Death Discov